484 related articles for article (PubMed ID: 25461191)
1. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
2. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
3. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.
Schultheis PJ; Fleming SM; Clippinger AK; Lewis J; Tsunemi T; Giasson B; Dickson DW; Mazzulli JR; Bardgett ME; Haik KL; Ekhator O; Chava AK; Howard J; Gannon M; Hoffman E; Chen Y; Prasad V; Linn SC; Tamargo RJ; Westbroek W; Sidransky E; Krainc D; Shull GE
Hum Mol Genet; 2013 May; 22(10):2067-82. PubMed ID: 23393156
[TBL] [Abstract][Full Text] [Related]
4. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ
PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2.
Kett LR; Stiller B; Bernath MM; Tasset I; Blesa J; Jackson-Lewis V; Chan RB; Zhou B; Di Paolo G; Przedborski S; Cuervo AM; Dauer WT
J Neurosci; 2015 Apr; 35(14):5724-42. PubMed ID: 25855184
[TBL] [Abstract][Full Text] [Related]
6. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation.
Tsunemi T; Ishiguro Y; Yoroisaka A; Valdez C; Miyamoto K; Ishikawa K; Saiki S; Akamatsu W; Hattori N; Krainc D
J Neurosci; 2020 Nov; 40(45):8618-8628. PubMed ID: 33046546
[TBL] [Abstract][Full Text] [Related]
7. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.
Ramonet D; Podhajska A; Stafa K; Sonnay S; Trancikova A; Tsika E; Pletnikova O; Troncoso JC; Glauser L; Moore DJ
Hum Mol Genet; 2012 Apr; 21(8):1725-43. PubMed ID: 22186024
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.
Usenovic M; Knight AL; Ray A; Wong V; Brown KR; Caldwell GA; Caldwell KA; Stagljar I; Krainc D
Hum Mol Genet; 2012 Sep; 21(17):3785-94. PubMed ID: 22645275
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes.
Kong SM; Chan BK; Park JS; Hill KJ; Aitken JB; Cottle L; Farghaian H; Cole AR; Lay PA; Sue CM; Cooper AA
Hum Mol Genet; 2014 Jun; 23(11):2816-33. PubMed ID: 24603074
[TBL] [Abstract][Full Text] [Related]
11. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
[TBL] [Abstract][Full Text] [Related]
12. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.
Tsunemi T; Hamada K; Krainc D
J Neurosci; 2014 Nov; 34(46):15281-7. PubMed ID: 25392495
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H
Fujii T; Nagamori S; Wiriyasermkul P; Zheng S; Yago A; Shimizu T; Tabuchi Y; Okumura T; Fujii T; Takeshima H; Sakai H
Nat Commun; 2023 Apr; 14(1):2174. PubMed ID: 37080960
[TBL] [Abstract][Full Text] [Related]
14. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
Park JS; Blair NF; Sue CM
Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of human Atp13a2Isoform-1 protein protects cells against manganese and starvation-induced toxicity.
Ugolino J; Dziki KM; Kim A; Wu JJ; Vogel BE; Monteiro MJ
PLoS One; 2019; 14(8):e0220849. PubMed ID: 31393918
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.
Gitler AD; Chesi A; Geddie ML; Strathearn KE; Hamamichi S; Hill KJ; Caldwell KA; Caldwell GA; Cooper AA; Rochet JC; Lindquist S
Nat Genet; 2009 Mar; 41(3):308-15. PubMed ID: 19182805
[TBL] [Abstract][Full Text] [Related]
17. Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Rajagopalan S; Rane A; Chinta SJ; Andersen JK
J Neurosci; 2016 Jan; 36(4):1086-95. PubMed ID: 26818499
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
19. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.
Tsunemi T; Krainc D
Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770
[TBL] [Abstract][Full Text] [Related]
20. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
